Pfizer Inc :Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis.Pfizer Inc - Jade Dare Trial Met Co-Primary And Key Secondary Endpoints And Demonstrated A Safety Profile Consistent With Previous Studies.Pfizer Inc - Study Showed That Abrocitinib Was Statistically Superior Compared To Dupilumab In Each Evaluated Efficacy Measure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments